Top

Published in:

Open Access 01-04-2020 | Cancer Biomarker | Original Article

Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis

Authors: Emilia Lubowicka, Monika Zbucka-Kretowska, Iwona Sidorkiewicz, Monika Zajkowska, Ewa Gacuta, Andrzej Puchnarewicz, Lech Chrostek, Maciej Szmitkowski, Sławomir Ławicki

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag – by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC – 93.10%, II – 82.76%, III and IV – 96.88%, total group – 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Jin L, Xu ZX (2015) Recent advances in the study of HPV-associated carcinogenesis. Virol Sin 30(2):101–106. https://doi.org/10.1007/s12250-015-3586-3 CrossRefPubMedPubMedCentral

Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A, Galazios G (2016) Cervical cancer: screening, diagnosis and staging. J BUON 21(2):320–325PubMed

Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605–612. https://doi.org/10.1158/0008-5472.CAN-05-4005 CrossRefPubMed

Achkova D, Maher J (2016) Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochem Soc Trans 44(2):333–341. https://doi.org/10.1042/BST20150245 CrossRefPubMed

Zajkowska M, Głażewska EK, Będkowska GE, Chorąży P, Szmitkowski M, Ławicki S (2016) Diagnostic power of vascular endothelial growth factor and macrophage Colony-stimulating factor in breast Cancer patients based on ROC analysis. Mediat Inflamm 2016:5962946. https://doi.org/10.1155/2016/5962946 CrossRef

Richardsen E, Uglehus RD, Johnsen SH, Busund LT (2015) Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res 35(2):865–874PubMed

Będkowska GE, Ławicki S, Gacuta E, Pawłowski P, Szmitkowski M (2015) M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. J Ovarian Res 8:27. https://doi.org/10.1186/s13048-015-0153-3 CrossRefPubMedPubMedCentral

Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata N (2014) Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan. J Gynecol Oncol 25(2):124–129. https://doi.org/10.3802/jgo.2014.25.2.124 CrossRefPubMedPubMedCentral

10.

Poonawalla IB, Piller LB, Lairson DR, Chan W, Du XL (2016) Use of hematopoietic growth factors and risk of thromboembolic and pulmonary toxicities in elderly patients with advanced ovarian Cancer. Womens Health Issues 26(5):574–583. https://doi.org/10.1016/j.whi.2016.05.007 CrossRefPubMed

11.

Aharinejad S, Salama M, Paulus P, Zins K, Berger A, Singer CF (2013) Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer 20(6):777–783. https://doi.org/10.1530/ERC-13-0198 CrossRefPubMed

12.

Ławicki S, Głażewska EK, Sobolewska M, Będkowska GE, Szmitkowski M (2016) Plasma levels and diagnostic utility of macrophage Colony-stimulating factor, matrix Metalloproteinase-9, and tissue inhibitor of Metalloproteinases-1 as new biomarkers of breast Cancer. Ann Lab Med 36(3):223–229. https://doi.org/10.3343/alm.2016.36.3.223 CrossRefPubMedPubMedCentral

13.

Rego SL, Helms RS, Dréau D (2014) Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-κB signaling. Angiogenesis 17(3):573–585. https://doi.org/10.1007/s10456-013-9405-2 CrossRefPubMed

14.

Björklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755(1):37–69. https://doi.org/10.1016/j.bbcan.2005.03.001 CrossRefPubMed

15.

Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87(3–4):287–297. https://doi.org/10.1016/j.biochi.2005.01.014 CrossRefPubMed

16.

Remillard TC, Bratslavsky G, Jensen-Taubman S, Stetler-Stevenson WG, Bourboulia D (2014) Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. Mol Cell Ther 2:17. https://doi.org/10.1186/2052-8426-2-17 CrossRefPubMedPubMedCentral

17.

Walsh LA, Cepeda MA, Damjanovski S (2012) Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells. J Cell Commun Signal 6(2):87–95. https://doi.org/10.1007/s12079-011-0157-8 CrossRefPubMedPubMedCentral

18.

Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253(1–2):269–285CrossRef

19.

Bourboulia D, Stetler-Stevenson WG (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20(3):161–168. https://doi.org/10.1016/j.semcancer.2010.05.002 CrossRefPubMedPubMedCentral

20.

Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1):55–71. https://doi.org/10.1016/j.bbamcr.2010.01.003 CrossRefPubMedPubMedCentral

21.

Kähäri VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31(1):34–45CrossRef

22.

Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, Reed N, Kesic V (2015) Follow-up in gynecological malignancies: a state of art. Int J Gynecol Cancer 25(7):1151–1164. https://doi.org/10.1097/IGC.0000000000000498 CrossRefPubMed

23.

Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB (2003) M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 171(5):2637–2643CrossRef

24.

Lawicki S, Bedkowska E, Gacuta-Szumarska E, Czygier M, Szmitkowski M (2007) The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients. Przegl Lek 64(12):987–990PubMed

25.

Ławicki S, Szmitkowski M, Wojtukiewicz M (2006) The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta 371(1–2):112–116. https://doi.org/10.1016/j.cca.2006.02.033 CrossRefPubMed

26.

Lawicki S, Gacuta-Szumarska E, Będkowska GE, Szmitkowski M (2012) Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors 30(6):357–366. https://doi.org/10.3109/08977194.2012.724407 CrossRefPubMed

27.

Mroczko B, Szmitkowski M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B (2007) Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. Int J Color Dis 22(1):33–38. https://doi.org/10.1007/s00384-006-0099-4 CrossRef

28.

Liu H, Zhang H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J, Sun Y (2016) Increased expression of CSF-1 associates with poor prognosis of patients with gastric Cancer undergoing gastrectomy. Medicine (Baltimore) 95(9):e2675. https://doi.org/10.1097/MD.0000000000002675 CrossRef

29.

Fingleton B (2006) Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11:479–491CrossRef

30.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10(22):7621–7628. https://doi.org/10.1158/1078-0432.CCR-04-1061 CrossRefPubMed

31.

Crawford HC, Matrisian LM (1994) Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14(1–6):234–245PubMed

32.

Ławicki S, Będkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M (2012) Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia Histochem Cytobiol 50(2):213–219CrossRef

33.

Ławicki S, Zajkowska M, Głażewska EK, Będkowska GE, Szmitkowski M (2016) Plasma levels and diagnostic utility of M-CSF, MMP-2 and its inhibitor TIMP-2 in the diagnostics of breast Cancer patients. Clin Lab 62(9):1661–1669PubMed

34.

Vasiliades G, Kopanakis N, Vasiloglou M, Zografos G, Margaris H, Masselou K, Kokosi E, Liakakos T (2012) Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers 27(3):e186–e194. https://doi.org/10.5301/JBM.2012.9348 CrossRefPubMed

35.

Ławicki S, Będkowska GE, Szmitkowski M (2013) VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. Growth Factors 31(3):98–105. https://doi.org/10.3109/08977194.2013.797900 CrossRefPubMed

36.

Ghosh A, Moirangthem A, Dalui R, Ghosh T, Bandyopadhyay A, Dasgupta A, Banerjee U, Jana N, Basu A (2014) Expression of matrix metalloproteinase-2 and 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age groups of premenopausal and postmenopausal women. J Cancer Res Clin Oncol 140(9):1585–1593. https://doi.org/10.1007/s00432-014-1695-2 CrossRefPubMed

37.

Lawicki S, Bedkowska E, Gacuta-Szumarska E, Knapp P, Szmitkowski M (2008) The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients. Pol Merkur Lekarski 25(145):38–42PubMed

Title: Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
Authors: Emilia Lubowicka
Monika Zbucka-Kretowska
Iwona Sidorkiewicz
Monika Zajkowska
Ewa Gacuta
Andrzej Puchnarewicz
Lech Chrostek
Maciej Szmitkowski
Sławomir Ławicki
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Cancer Biomarker
Cervical Cancer
Cervical Cancer
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00626-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer

Total Serum Cholesterol and Pancreatic Cancer Risk: What Is the Link?

Solid-pseudopapillary Neoplasms of the Pancreas is still an Enigma: a Clinicopathological Review

The Impact of MicroRNA-133a on Prognosis and Clinicopathological Parameters for Digestive System Cancers: a Comprehensive Study Based on Meta-Analysis and TCGA Database

Adaptation of Fatigue Affected Changes in Muscle EMG Frequency Characteristics for the Determination of Training Load in Physical Therapy for Cancer Patients

MicroRNA-182-5p Modulates Oral Squamous Cell Carcinoma Migration and Invasion Via Targeting MTSS1 Gene

Keynote webinar | Spotlight on antibody–drug conjugates in cancer